$194.97
0.46%
NYSE, Jan 02, 10:00 pm CET
ISIN
US0758871091
Symbol
BDX

Becton, Dickinson & Stock price

$194.94
+4.47 2.35% 1M
+17.67 9.97% 6M
+0.87 0.45% YTD
-31.55 13.93% 1Y
-59.36 23.34% 3Y
-49.48 20.24% 5Y
+50.70 35.15% 10Y
+136.37 232.81% 20Y
NYSE, Closing price Fri, Jan 02 2026
+0.87 0.45%

New AI Insights on Becton, Dickinson & Insights AI Insights on Becton, Dickinson &

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$55.5b
Enterprise Value
$74.1b
Net debt
$18.5b
Cash
$649.0m
Shares outstanding
285.4m
Valuation (TTM | estimate)
P/E
33.5 | 13.0
P/S
2.5 | 2.4
EV/Sales
3.4 | 3.3
EV/FCF
27.7
P/B
2.2
Dividends
DPS
$4.16
Yield 1Y | 5Y
2.1% | 1.5%
Growth 1Y | 5Y
9.5% | 6.2%
Payout 1Y | 3Y
71.5% | 69.8%
Increased
25 Years
Financials (TTM | estimate)
Revenue
$21.8b | $22.7b
EBITDA
$5.9b | $6.6b
EBIT
$3.4b | $5.7b
Net Income
$1.7b | $4.3b
Free Cash Flow
$2.7b
Growth (TTM | estimate)
Revenue
8.2% | 4.0%
EBITDA
13.8% | 9.7%
EBIT
18.6% | 61.5%
Net Income
-2.8% | 155.4%
Free Cash Flow
-13.1%
Margin (TTM | estimate)
Gross
45.8%
EBITDA
27.0% | 28.8%
EBIT
15.7%
Net
7.7% | 18.9%
Free Cash Flow
12.2%
Financial Health
Equity Ratio
45.9%
Return on Equity
6.6%
ROCE
7.3%
ROIC
5.8%
Debt/Equity
0.8
More
EPS
$5.8
FCF per Share
$9.4
Short interest
1.9%
Employees
74k
Rev per Employee
$300.0k
Show more

Is Becton, Dickinson & a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Becton, Dickinson & Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Becton, Dickinson & forecast:

7x Buy
39%
11x Hold
61%

Analyst Opinions

18 Analysts have issued a Becton, Dickinson & forecast:

Buy
39%
Hold
61%

Financial data from Becton, Dickinson &

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
21,840 21,840
8% 8%
100%
- Direct Costs 11,839 11,839
7% 7%
54%
10,001 10,001
9% 9%
46%
- Selling and Administrative Expenses 5,277 5,277
9% 9%
24%
- Research and Development Expense 1,264 1,264
6% 6%
6%
5,890 5,890
14% 14%
27%
- Depreciation and Amortization 2,462 2,462
8% 8%
11%
EBIT (Operating Income) EBIT 3,428 3,428
19% 19%
16%
Net Profit 1,678 1,678
3% 3%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Becton, Dickinson & directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Becton, Dickinson & Stock News

Positive
Seeking Alpha
4 days ago
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Neutral
Seeking Alpha
8 days ago
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.
Neutral
PRNewsWire
18 days ago
BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study FRANKLIN LAKES, N.J. , Dec. 18, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immun...
More Becton, Dickinson & News

Company Profile

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Head office United States
CEO Thomas Polen
Employees 74,000
Founded 1897
Website www.bd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today